Amelia Zelnak

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

Aditya Bardia, Sara A. Hurvitz, Sara M. Tolaney et al. · New England Journal of Medicine · 2021 · 1.5K citations · Full text

Medicine, Oncology, Pharmacology +17

Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial

Nancy U. Lin, Virginia F. Borges, Carey K. Anders et al. · Journal of Clinical Oncology · 2020 · 549 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer

Aditya Bardia, Sara M. Tolaney, Kevin Punie et al. · Annals of Oncology · 2021 · 299 citations · Full text

Medicine, Oncology, Pharmacology +16

Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases

Nancy U. Lin, Rashmi K. Murthy, Vandana G. Abramson et al. · JAMA Oncology · 2022 · 197 citations · Full text

Medicine, Oncology, Pharmacology +17

Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: MAINTAIN Trial

Kevin Kalinsky, Melissa Accordino, Codruța Chiuzan et al. · Journal of Clinical Oncology · 2023 · 191 citations

Medicine, Oncology, Pharmacology +17